Nalini Janakiraman

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Human marrow stromal cell therapy for stroke in rat

Y. Li, J. Chen, Xinyuan Chen et al. · Neurology · 2002 · 869 citations

Life Sciences, Neurology, Neuroscience +14

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20⁺B-Cell Non-Hodgkin's Lymphoma

Thomas E. Witzig, Christine A. White, Gregory A. Wiseman et al. · Journal of Clinical Oncology · 1999 · 539 citations

Medicine, Hematology, Oncology +17

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Lawrence D. Piro, Christine A. White, A.J. Grillo-López et al. · Annals of Oncology · 1999 · 368 citations · Full text

Life Sciences, Immunology, Oncology +13

Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production11Abbreviations: CTLs, cytotoxic T lymphocytes; LAK cells, lymphokine activated killer cells; IL-2, interleukin-2; IFN-γ, interferon-gamma; TNF-α, tumor necrosis factor-α NF-κB, nuclear factor kappa B; Con A, concanavalin A; HBSS, Hanks’ balanced salt solution; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; RT-PCR, reverse transcription-polymerase chain reaction; LPS, lipopolysaccharide; and EMSA, electrophoretic mobility shift assay.

Xiaohua Gao, Yong Xu, Nalini Janakiraman et al. · Biochemical Pharmacology · 2001 · 248 citations

Life Sciences, Immunology, Pharmacology +17